{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:19:53Z","timestamp":1789885193352,"version":"4.0.1"},"reference-count":69,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["1R01HL15583401"],"award-info":[{"award-number":["1R01HL15583401"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Pheochromocytomas and paragangliomas (PPGL) are rare causes of secondary hypertension, but when unrecognized, they can lead to serious complications. Data regarding PPGL screening are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to assess the rates and patterns of PPGL screening among eligible patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective review of adults with hypertension seen in outpatient clinics of a large academic center between January 1, 2017, and June 30, 2020. We included patients with treatment-resistant hypertension, hypertension at age &amp;lt; 35 years, and\/or adrenal mass(es).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 203 535 patients with hypertension identified, 71 088 (35%) met \u2265 1 inclusion criteria, and 2013 (2.83%) were screened for PPGL. Patients screened were younger (56.2 \u00b1 17.4 vs 64.0 \u00b1 17.1 years), more often women (54.1% vs 44.2%), and never-smokers (54.6% vs 47.5%, P &amp;lt; 0.001 for all). The rate of screening was highest in patients with hypertension and adrenal mass(es) (51.7%, vs 3.9% in patients with early-onset hypertension, and 2.4% in those with treatment-resistant hypertension). Multivariable logistic regression showed higher odds ratio (OR) of PPGL screening in women (OR [95% CI]: 1.48 [1.34-1.63]); Black vs White patients (1.35 [1.19-1.53]); patients with adrenal mass(es) (55.1 [44.53-68.15]), stroke (1.34 [1.16-1.54]), dyslipidemia (1.41 [1.26-1.58]), chronic kidney disease (1.40 [1.26-1.56]), and obstructive sleep apnea (1.96 [1.76-2.19]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PPGL screening is pursued in roughly half of patients with adrenal nodules and hypertension, but rarely in patients with treatment-resistant or early-onset hypertension. Similar to screening for other forms of secondary hypertension, PPGL screening occurs more often after serious complications develop.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac701","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:30:16Z","timestamp":1670272216000},"page":"e343-e349","source":"Crossref","is-referenced-by-count":4,"title":["Rates of Pheochromocytoma\/Paraganglioma Screening in At-Risk Populations"],"prefix":"10.1210","volume":"108","author":[{"given":"Seda","family":"Grigoryan","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Nhan","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Urban","sequence":"additional","affiliation":[{"name":"Michigan State University College of Human Medicine , Grand Rapids, MI 49503 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-8206","authenticated-orcid":false,"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-6190","authenticated-orcid":false,"given":"Adina F","family":"Turcu","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"10","key":"2023051701084200800_dgac701-B1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jch.13364","article-title":"Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC\/AHA hypertension guideline","volume":"20","author":"Ritchey","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"2023051701084200800_dgac701-B2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"2023051701084200800_dgac701-B3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"9","key":"2023051701084200800_dgac701-B4","first-page":"1","article-title":"Deaths: final data for 2017","volume":"68","author":"Kochanek","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"11","key":"2023051701084200800_dgac701-B5","doi-asserted-by":"crossref","first-page":"e008731","DOI":"10.1161\/JAHA.118.008731","article-title":"Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003-2014","volume":"7","author":"Kirkland","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"9455","key":"2023051701084200800_dgac701-B6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"2023051701084200800_dgac701-B7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.122.19222","article-title":"Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020","volume":"79","author":"Muntner","year":"2022","journal-title":"Hypertension"},{"key":"2023051701084200800_dgac701-B8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","article-title":"Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study","volume":"218","author":"Borghi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"2023051701084200800_dgac701-B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","article-title":"Hypertension treatment and control in five European countries, Canada, and the United States","volume":"43","author":"Wolf-Maier","year":"2004","journal-title":"Hypertension"},{"issue":"10060","key":"2023051701084200800_dgac701-B10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"2023051701084200800_dgac701-B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11936-019-0790-8","article-title":"The demystification of secondary hypertension: diagnostic strategies and treatment algorithms","volume":"21","author":"Hirsch","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"1","key":"2023051701084200800_dgac701-B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"11","key":"2023051701084200800_dgac701-B13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2018.07.008","article-title":"Prevention and control of hypertension: JACC health promotion series","volume":"72","author":"Carey","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2023051701084200800_dgac701-B14","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023051701084200800_dgac701-B15","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2023051701084200800_dgac701-B16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"3","key":"2023051701084200800_dgac701-B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"issue":"5","key":"2023051701084200800_dgac701-B18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00004872-199405000-00015","article-title":"The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients","volume":"12","author":"Anderson","year":"1994","journal-title":"J Hypertens"},{"issue":"11","key":"2023051701084200800_dgac701-B19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"2023051701084200800_dgac701-B20","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023051701084200800_dgac701-B21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11886-021-01485-4","article-title":"Pheochromocytoma and paraganglioma in pregnancy: a new era","volume":"23","author":"Gruber","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"2023051701084200800_dgac701-B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2482-15-11","article-title":"Hypertensive crisis caused by electrocauterization of the adrenal gland during hepatectomy","volume":"15","author":"Doo","year":"2015","journal-title":"BMC Surg"},{"issue":"23","key":"2023051701084200800_dgac701-B23","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"2023051701084200800_dgac701-B24","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1210\/jc.2003-031127","article-title":"The economic implications of three biochemical screening algorithms for pheochromocytoma","volume":"89","author":"Sawka","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023051701084200800_dgac701-B25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023051701084200800_dgac701-B26","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"2023051701084200800_dgac701-B27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"3","key":"2023051701084200800_dgac701-B28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. Veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"issue":"14","key":"2023051701084200800_dgac701-B29","doi-asserted-by":"crossref","first-page":"e025952","DOI":"10.1161\/JAHA.122.025952","article-title":"Primary aldosteronism screening rates differ with sex, race, and comorbidities","volume":"11","author":"Turcu","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2023051701084200800_dgac701-B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08037050310009950","article-title":"High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension","volume":"12","author":"Martell","year":"2003","journal-title":"Blood Press"},{"issue":"4","key":"2023051701084200800_dgac701-B31","first-page":"1480","article-title":"Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center","volume":"86","author":"Plouin","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023051701084200800_dgac701-B32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ejso.2004.03.006","article-title":"Mortality associated with pheochromocytoma in a large Swedish cohort","volume":"30","author":"Khorram-Manesh","year":"2004","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2023051701084200800_dgac701-B33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(20)30363-6","article-title":"Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature","volume":"9","author":"Bancos","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2023051701084200800_dgac701-B34","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/HJH.0b013e32834a4ce9","article-title":"Cardiovascular manifestations of phaeochromocytoma","volume":"29","author":"Prejbisz","year":"2011","journal-title":"J Hypertens"},{"issue":"5","key":"2023051701084200800_dgac701-B35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0032-1306294","article-title":"High incidence of cardiovascular complications in pheochromocytoma","volume":"44","author":"Zelinka","year":"2012","journal-title":"Horm Metab Res"},{"key":"2023051701084200800_dgac701-B36","first-page":"1","article-title":"Hypertension prevalence among adults aged 18 and over: United States, 2017-2018","volume":"364","author":"Ostchega","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"5","key":"2023051701084200800_dgac701-B37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00345-012-1011-1","article-title":"Adrenal tumours are more predominant in females regardless of their histological subtype: a review","volume":"31","author":"Audenet","year":"2013","journal-title":"World J Urol"},{"issue":"6","key":"2023051701084200800_dgac701-B38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1530\/EC-21-0196","article-title":"Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study","volume":"10","author":"Podbregar","year":"2021","journal-title":"Endocr Connect"},{"issue":"4","key":"2023051701084200800_dgac701-B39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/eje.0.1490273","article-title":"Prevalence and natural history of adrenal incidentalomas","volume":"149","author":"Barzon","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"1-3","key":"2023051701084200800_dgac701-B40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12020-008-9108-4","article-title":"Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma","volume":"34","author":"Lai","year":"2008","journal-title":"Endocrine"},{"issue":"4","key":"2023051701084200800_dgac701-B41","first-page":"e29","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"2023051701084200800_dgac701-B42","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"2023051701084200800_dgac701-B43","first-page":"7","article-title":"Evaluation and management of the incidental adrenal mass","volume":"16","author":"Arnold","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"6","key":"2023051701084200800_dgac701-B44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/EJE-10-1147","article-title":"AME Position statement on adrenal incidentaloma","volume":"164","author":"Terzolo","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023051701084200800_dgac701-B45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/jc.2018-01532","article-title":"CT Characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma","volume":"104","author":"Canu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023051701084200800_dgac701-B46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.21037\/gs.2020.03.04","article-title":"Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis","volume":"9","author":"Gruber","year":"2020","journal-title":"Gland Surg"},{"issue":"6","key":"2023051701084200800_dgac701-B47","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1210\/jc.2012-1061","article-title":"Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?","volume":"97","author":"Sane","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023051701084200800_dgac701-B48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1378\/chest.09-0360","article-title":"Interactions between obesity and obstructive sleep apnea: implications for treatment","volume":"137","author":"Romero-Corral","year":"2010","journal-title":"Chest"},{"issue":"6","key":"2023051701084200800_dgac701-B49","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1378\/chest.07-1170","article-title":"Obstructive sleep apnea and resistant hypertension: a case-control study","volume":"132","author":"Goncalves","year":"2007","journal-title":"Chest"},{"issue":"12","key":"2023051701084200800_dgac701-B50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","article-title":"High prevalence of unrecognized sleep apnoea in drug-resistant hypertension","volume":"19","author":"Logan","year":"2001","journal-title":"J Hypertens"},{"issue":"3","key":"2023051701084200800_dgac701-B51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1378\/chest.120.3.887","article-title":"Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea","volume":"120","author":"Ziegler","year":"2001","journal-title":"Chest"},{"issue":"6","key":"2023051701084200800_dgac701-B52","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1378\/chest.103.6.1763","article-title":"Augmented resting sympathetic activity in awake patients with obstructive sleep apnea","volume":"103","author":"Carlson","year":"1993","journal-title":"Chest"},{"issue":"5","key":"2023051701084200800_dgac701-B53","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2003-031348","article-title":"Obstructive sleep apnea presenting as pseudopheochromocytoma: a case report","volume":"89","author":"Hoy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023051701084200800_dgac701-B54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004872-199917010-00010","article-title":"Effects of obstructive sleep apnea on endothelin-1 and blood pressure","volume":"17","author":"Phillips","year":"1999","journal-title":"J Hypertens"},{"issue":"4","key":"2023051701084200800_dgac701-B55","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1172\/JCI118235","article-title":"Sympathetic neural mechanisms in obstructive sleep apnea","volume":"96","author":"Somers","year":"1995","journal-title":"J Clin Invest"},{"key":"2023051701084200800_dgac701-B56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2014.07.004","article-title":"Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a systematic review from sham CPAP randomized controlled trials","volume":"21","author":"Jullian-Desayes","year":"2015","journal-title":"Sleep Med Rev"},{"issue":"10","key":"2023051701084200800_dgac701-B57","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1164\/rccm.201106-0964OC","article-title":"Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial","volume":"184","author":"Kohler","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2023051701084200800_dgac701-B58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5664\/jcsm.27770","article-title":"Obstructive sleep apnea presenting as pseudopheochromocytoma","volume":"6","author":"Cheezum","year":"2010","journal-title":"J Clin Sleep Med"},{"issue":"17","key":"2023051701084200800_dgac701-B59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanova","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2023051701084200800_dgac701-B60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0046-8177(73)80012-7","article-title":"High altitude hypoxia and chemodectomas","volume":"4","author":"Saldana","year":"1973","journal-title":"Hum Pathol"},{"issue":"5","key":"2023051701084200800_dgac701-B61","doi-asserted-by":"crossref","first-page":"e0127471","DOI":"10.1371\/journal.pone.0127471","article-title":"3rd. Oxygen concentration controls epigenetic effects in models of familial paraganglioma","volume":"10","author":"Her","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"2023051701084200800_dgac701-B62","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1101\/gad.250167.114","article-title":"Human high-altitude adaptation: forward genetics meets the HIF pathway","volume":"28","author":"Bigham","year":"2014","journal-title":"Genes Dev"},{"issue":"19","key":"2023051701084200800_dgac701-B63","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"2023051701084200800_dgac701-B64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J Mol Med (Berl)"},{"issue":"9","key":"2023051701084200800_dgac701-B65","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2023051701084200800_dgac701-B66","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2023051701084200800_dgac701-B67","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023051701084200800_dgac701-B68","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/jc.2005-0064","article-title":"Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2","volume":"90","author":"Machens","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023051701084200800_dgac701-B69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CRD.0000000000000141","article-title":"Cardiovascular manifestations of pheochromocytoma","volume":"25","author":"Gu","year":"2017","journal-title":"Cardiol Rev"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac701\/49570489\/dgac701.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/6\/e343\/50355181\/dgac701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/6\/e343\/50355181\/dgac701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:10:56Z","timestamp":1684285856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/6\/e343\/6873931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2023,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac701","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2022,12,5]]}}}